ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1138

Estimation of Clinically Important Differences in Patient-Reported Outcomes Measurement Information System (PROMIS) Measures in Juvenile Myositis

Madison Wolfe1, Amanda Robinson2, Jin-Shei Lai3, Theresa Coles4, Elizabeth Gray3, Rowland Chang3, David Cella3 and Kaveh Ardalan5, 1Creighton University School of Medicine, Omaha, NE, 2Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Duke University, Durham, 5Duke University Medical Center, Durham, NC

Meeting: ACR Convergence 2020

Keywords: dermatomyositis, Outcome measures, Patient reported outcomes, Pediatric rheumatology, Psychometrics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile myositis (JM) causes weakness, rashes, pain, and fatigue, thereby impacting health-related quality of life (HRQoL). Patient-Reported Outcomes Measurement Information System (PROMIS®) measures have undergone initial validation in JM, but clinical interpretability is limited. Estimates of clinically important differences (CIDs) have not yet been determined for PROMIS measures in JM. This study estimates CIDs of PROMIS fixed short forms in JM.

Methods: JM patients (5-17 yo) and their parents were recruited at routine clinic visits. Clinical/demographic data were collected. Patients (8-17 yo) and parents (5-17 yo) completed PROMIS pediatric fixed short forms for Anxiety, Depressive Symptoms, Mobility, Upper Extremity Function, Fatigue, and Pain Interference domains. Distribution-based estimates (i.e. 0.5 standard deviation) of CIDs were calculated. Cross-sectional and longitudinal anchor-based estimation of CIDs was performed. Longitudinal anchor-based CID estimates (i.e. change in PROMIS score associated with change in anchor variable) were calculated for patient-parent dyads with data collected at 2 study visits. Anchor variables collected at study visits included: Physician’s Global Assessment of Disease Activity (PGA), muscle enzymes, Disease Activity Score Muscle and Skin Domains (MDAS, SDAS), Childhood Myositis Assessment Scale (CMAS), PedsQL Generic Core Scales (PedsQL-GC) and PedsQL Rheumatology Modules (PedsQL-RM). Anchor variables were grouped into clinically distinct categories based on published score cutoffs. Criteria for reporting anchor-based CID estimates included: 1) Spearman’s correlation ≥0.3; 2) n ≥5 per clinically distinct anchor variable category; 3) effect size (i.e. Cohen’s D) > 0.2. Differences in mean PROMIS scores across adjacent clinically distinct anchor variable categories were reported as CID estimates. Mean standard error of measurement (SEM) for each PROMIS domain served as the lower bound for CID estimates.

Results: Seventy-five patient-parent dyads enrolled, with descriptive data in Table 1. Mean SEM for PROMIS child report and parent report were respectively: Anxiety (4.7; 3.9), Depressive Symptoms (4.7; 4.5), Fatigue (4.6; 3.5), Mobility (5.3; 4.6), Pain Interference (4.4; 3.9), Upper Extremity Function (6.5; 5.7). Distribution-based PROMIS CID estimates ranged 3.4-6.1 and 4.7-6.3 for child report and parent report respectively. Cross-sectional anchor-based CID estimates are shown in Table 2. Longitudinal anchor-based CID estimates are presented in Table 3.

Conclusion: Our CID estimates enhance interpretability of PROMIS measures in JM by linking differences in PROMIS measures with relevant clinical and patient-reported anchors. CIDs can support the design and power calculations for future studies (e.g. clinical trials). Future multicenter studies should enhance precision and generalizability of CID estimates and assess differences in CIDs by disease status (e.g. high vs low disease activity).

Table 1: Descriptive Statistics

Table 2: Cross-Sectional Anchor-Based Clinically Important Differences (CIDs)

Table 3: Longitudinal Anchor-Based Clinically Important Differences (CIDs)


Disclosure: M. Wolfe, None; A. Robinson, None; J. Lai, None; T. Coles, None; E. Gray, None; R. Chang, None; D. Cella, None; K. Ardalan, None.

To cite this abstract in AMA style:

Wolfe M, Robinson A, Lai J, Coles T, Gray E, Chang R, Cella D, Ardalan K. Estimation of Clinically Important Differences in Patient-Reported Outcomes Measurement Information System (PROMIS) Measures in Juvenile Myositis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/estimation-of-clinically-important-differences-in-patient-reported-outcomes-measurement-information-system-promis-measures-in-juvenile-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/estimation-of-clinically-important-differences-in-patient-reported-outcomes-measurement-information-system-promis-measures-in-juvenile-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology